Introduction {#S1}
============

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by a reduced platelet count and an increased risk of bleeding ([@B1]). The pathogenesis of ITP includes enhanced platelet clearance and impaired platelet production, which is related to T cell-mediated effects, B cell-mediated effects, tolerance checkpoint defects, and more ([@B2], [@B3]). Although immense research has improved our understanding of ITP, the etiology is still not completely clear. However, it has been widely accepted that both genetic and environmental factors play a significant role in the pathogenesis of ITP ([@B4]).

Autoimmune disease is characterized by self-antigen-induced chronic activation of immune system and eventually leads to tissue inflammation in genetically predisposed individuals ([@B5]). ITP is an autoimmune disease and closely related to inflammation ([@B6], [@B7]). Besides, inflammation can trigger ITP. For example, serum uric acid, an inflammatory mediator, played a pathophysiological role in the occurrence of ITP ([@B8]). However, ITP can also induce inflammation through platelet dysfunction. Recent research revealed that the acute phase of platelet destruction in severe ITP may trigger inflammation in the lung, which may induce interstitial lung disease ([@B9]). Furthermore, platelets mediate inflammation and immune-mediated disorders through multiple mechanisms, such as release of pro-inflammatory mediators, surface inflammation-related molecules, and interaction with leukocytes and endothelial cells ([@B10], [@B11]). Even after being phagocytosed by the mononuclear phagocyte system, platelets modulated survival surface molecules in monocytes ([@B12]). In others words, platelets regulated inflammation even after being eliminated from the circulation.

Single-nucleotide polymorphisms (SNPs), the most common pattern of genetic variants, have drawn attention because of their universal distribution and gradually uncovered biological functions ([@B13]). Many SNPs of inflammatory cytokine genes, including *IL-17F, IL-10, TNFA, TNFB, TGF-beta 1, IL-6, INF-gamma*, and *IL-1A*, influence patients' susceptibility to ITP ([@B14]--[@B18]). Among them, *IL-17F* rs763780 G allele has been identified as a protective factor in ITP, while *TNFB* + 252G/A A allele was a risk factor. There were also some SNPs associated with the severity of ITP. *IL-10* rs1800872 AA genotype presented a significant association with severity of ITP in a cohort of Egyptian population (*p* = 0.008) ([@B14]). The *IL-10* gene polymorphism was also identified to be associated with the severity in Japanese population (*p* = 0.01) ([@B19]). When it comes to corticosteroid sensitivity of ITP patients, an earlier study reported that stromal cell-derived factor-1 (*SDF-1*) rs2297630 GA and AA genotypes significantly increased the corticosteroid treatment sensitivity compared with GG genotype (*p* = 0.007) ([@B20]). Interestingly, a recent study showed that this SDF-1 polymorphism was associated with corticosteroid dependence in pediatric ITP patients ([@B21]). Furthermore, researchers identified that ATP-binding cassette gene B1 gene (*ANCB1*) G2677T/A polymorphism was significantly associated with corticosteroid sensitivity ([@B22]). Besides, there were several researches on the association between SNPs and the refractoriness of ITP. For example, it was identified that *TNFA*-308G/A A allele was a risk factor for refractory ITP ([@B17]). In addition, genetic variants of a cluster of inflammation-related genes, including *CD24, CD226, FCRL3, IL2, IRF5, ITGAM, NLRP3, CARD8, PTPN22, SH2B3, STAT4, TNFAIP3*, and *TRAF1*, are associated with diverse autoimmune diseases. For example, the rs8734 polymorphism in *CD24* was associated with susceptibility to diverse autoimmune diseases including rheumatoid arthritis (RA), autoimmune thyroid disease (AITD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and inflammatory bowel disease (IBD) ([@B23]--[@B29]). In addition, four SNP candidates in *FCRL3*, including rs11264799, rs7528684, rs945635, and rs3761959, have been identified as potential risk factors in multiple autoimmune diseases, including RA, AITD, SLE, MS, autoimmune Addison's disease, and autoimmune pancreatitis ([@B30]--[@B36]). Finally, rs6822844, located between the *IL2* gene and the nearby *IL21* gene, was associated with RA, IBD, type 1 diabetes, and psoriasis ([@B37]--[@B40]). Therefore, there are multiple inflammation-related SNPs that are robustly associated with multiple autoimmune diseases. The above studies demonstrated that multiple genetic factors involved in the pathogenesis of ITP and other autoimmune diseases. However, most previous researches only verified the associations between SNPs and ITP susceptibility or ITP treatment. None of them associated the polymorphisms with complete clinical data including susceptibility, severity, corticosensitivity, and refractoriness.

Given that ITP is an inflammatory and autoimmune disease and given the above associations between inflammation-related SNPs and other autoimmune diseases, we hypothesized that these SNPs were also associated with primary ITP. The aim of our study was to investigate the association between inflammation-related gene polymorphisms and the pathogenesis of primary ITP in the Chinese Han population.

Materials and Methods {#S2}
=====================

Study Participants {#S2-1}
------------------

In this case--control study, 312 ITP inpatients were recruited between January 2007 and April 2016 from the Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.

Patients were diagnosed with primary ITP according to the International Working Group guidelines ([@B41]). And other autoimmune diseases or underlying immune dysregulation were excluded by medical history, clinical manifestations, physical examinations, radiologic findings and laboratory findings such as HIV and HCV testing, direct antiglobulin test, antiphospholipid antibody testing, antinuclear antibody testing, antithyroid antibody, and thyroid function testing, and testing for other acute and persistent infections. Cases were stratified by severity, corticosteroid sensitivity, and refractoriness based on the standardized definitions ([@B1]). Severe ITP is defined by the presence of bleeding symptoms at presentation sufficient to mandate treatment, or by the occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose to relieve symptoms caused by low platelet count (platelet count may even \<10 × 10^9^/L). The corticosteroid regimen is dexamethasone 40 mg p.o. daily for four consecutive days (non-responders received an additional 4-day course of dexamethasone) or prednisone 1.0 mg/kg body weight p.o. daily for four consecutive weeks. Corticosteroid sensitivity is defined as a platelet count ≥30 × 10^9^/L with at least a twofold increase from the baseline count and without bleeding after corticosteroid management. Requirements for additional interventions were considered as corticosteroid resistance. Refractory ITP patients satisfy two criteria. First, they should fail splenectomy. Second, they either manifest severe ITP or have a risk of bleeding that required therapy in the opinion of the attending physician.

For the control group, 205 healthy participants were enrolled. Controls were randomly selected from healthy volunteers with no symptoms of ITP and no history of other autoimmune diseases. All participants were Han Chinese and no genetic associations were found between any participants.

The study was approved by the Medical Ethical Committee of Qilu Hospital, Shandong University. Written informed consent was obtained from each participant in accordance with the Declaration of Helsinki.

DNA Extraction and Genotyping {#S2-2}
-----------------------------

Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) that had been isolated from whole blood samples (5 mL) from participants by a standard protocol. DNA concentration and purity were accessed at 260/280 absorbance by a NanoDrop spectrophotometer. The DNA extraction was stored at −20°C until genotyping. Inflammation-related SNPs (summarized in Table [1](#T1){ref-type="table"}) genotyping was performed on a MassArray system (Sequenom iPLEXassay, BGI Tech., Beijing, China), which is based on a multiplex PCR reaction, a locus-specific single-base extension reaction, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

###### 

Selected genes and SNPs.

  Genes     SNPs
  --------- ---------------------------------------------
  CD24      rs8734
  FCRL3     rs11264799, rs7528684, rs945635, rs3761959
  CD226     rs763361
  IL2       rs6822844
  IRF5      rs2004640, rs2280714, rs10954213
  ITGAM     rs1143679
  NLRP3     rs35829419, rs4353135, rs10754558
  CARD8     rs2043211
  PTPN22    rs33996649, rs1310182
  SH2B3     rs3184504
  STAT4     rs7574865, rs10181656
  TNFAIP3   rs6920220, rs10499194, rs2230926, rs5029939
  TRAF1     rs10818488

*SNP, single-nucleotide polymorphism*.

Statistical Analysis {#S2-3}
--------------------

The *p* value of the Hardy--Weinberg equilibrium (HWE) was calculated using the calculator available at the Helmholtz Center Munich website. In addition to allelic frequencies, we analyzed genotypic frequencies under three genetic models, specifically, the codominant, dominant, and recessive models. Associations between the SNPs and ITP susceptibility, severity, corticosteroid sensitivity, and refractoriness were calculated by a chi-squared (χ^2^) test or a Fisher's exact test. Univariate and multivariate binary logistic regression analyses were used to analyze adjusted *p* values and odds ratios (ORs) with a corresponding 95% confidence interval (95% CI). A two-tailed *p* \< 0.05 (or adjusted *p* value by Bonferroni multiple testing) was considered statistically significant. All statistical analyzes were performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA).

RNA Extraction and Real-time RT-PCR of TNFAIP3 {#S2-4}
----------------------------------------------

Total RNA of PBMCs was isolated by TRIzol reagent (Invitrogen). RNA was converted into cDNA using the PrimeScript RT reagent kit (Perfect Real Time; Takara) according to the manufacturer's instructions. Multiplex real-time RT-PCR was performed for *TNFAIP3* and the endogenous control β-actin on an ABI PRISM_7500 Sequence Detection System (Applied Biosystems) using SYBR Green (Toyobo) as a double-strand DNA-specific binding dye. The primers for all mRNA assays were intron spanning. The PCR reactions were cycled 40 times after initial denaturation (95°C, 10 min) at 95°C for 15 s and at 60°C for 30 s. The primers for *TNFAIP3* and β-actin are as follows: *TNFAIP3* forward: GTGTATTTTGGGACTCCAGA, *TNFAIP3* reverse: ACTTCTGGCAGTATCCTTCA; β-actin forward: CACCAACTGGGACGACAT, β-actin reverse: GCACAGCCTGGATAGCAAC. We used the comparative threshold cycle (*C*~t~) method for relative quantification of TNFAIP3 mRNA according to relative expression software tool (Michael) ([@B42]). The amplification efficiency between the target (*TNFAIP3*) and the reference control (β-actin) were compared to use the delta *C*~t~ (ΔΔ*C*~t~) calculation.

Results {#S3}
=======

Study Population {#S3-1}
----------------

Demographic and clinical characteristics of controls and ITP patients are summarized in Table [2](#T2){ref-type="table"}. All inflammation-related SNPs in the control group were in accordance with HWE. No significant deviations were observed after Bonferroni multiple correction (*p* \> 0.002, Table S1 in Supplementary Material).

###### 

Demographic and clinical characteristics.

                              Controls        ITP patients
  --------------------------- --------------- ---------------
  No.                         205             312
  Age, mean ± SD              45.72 ± 13.41   39.96 ± 13.69
  Gender (M/F)                75/130          116/196
  ITP severity, *n* (%)                       
   Severe ITP                 NA              189 (60.6)
   Non-severe ITP             NA              123 (39.4)
  Treatment, *n* (%)                          
   No use of corticosteroid   NA              50 (16.0)
   Corticosteroid-sensitive   NA              156 (50.0)
   Corticosteroid-resistant   NA              106 (34.0)
   Refractory ITP             NA              21 (6.7)
   Non-refractory ITP         NA              291 (93.3)

*M, male; F, female; NA, not applicable; ITP, immune thrombocytopenia*.

Association between Inflammation-Related SNPs and ITP Susceptibility {#S3-2}
--------------------------------------------------------------------

Four genetic models were used to analyze the association between the 25 inflammation-related SNPs and ITP. We analyzed the relationship between every single locus and the susceptibility to ITP by a chi-squared (χ^2^) test or a Fisher's exact test (Table S1 in Supplementary Material). Preliminary screening showed that allelic frequencies of rs8734 in *CD24* and genotypic frequencies of rs11264799 in *FCRL3* under the codominant model were significantly associated with susceptibility to ITP (*p* \< 0.05). In addition, both the allelic and genotypic frequencies of rs10499194 in *TNFAIP3* under the codominant and dominant models were significantly associated with the susceptibility to ITP (*p* \< 0.05). Among the above SNPs, only rs10499194 was associated with susceptibility of ITP after Bonferroni multiple correction.

Univariate logistic regression analysis revealed that for rs8734 in *CD24*, allele A in place of G was significantly associated with susceptibility to ITP after adjusting for age and gender (*p* = 0.035, Table [3](#T3){ref-type="table"}). For rs11264799 in *FCRL3*, the CT rather than CC genotype was significantly associated with susceptibility to ITP under the codominant model (*p* = 0.037, Table [3](#T3){ref-type="table"}). For rs10499194 in *TNFAIP3*, CT and CC/CT genotypes were both statistically significant compared to CC (*p* = 0.001 and *p* = 0.000, respectively, Table [3](#T3){ref-type="table"}). rs10499194 allelic distribution also showed a statistically significant difference (*p* = 0.003; Table [3](#T3){ref-type="table"}). Interestingly, all three inflammation-related polymorphisms demonstrated a protective effect. Among these polymorphisms, only rs10499194 presented a significant association with susceptibility to ITP with univariate logistic regression analysis after Bonferroni multiple correction.

###### 

Association between selected SNPs and ITP risk.

  Gene      SNP          Model/allele   Genotype/allele   Controls   ITP patients   OR (95% CI)   Adjusted *p* value                           
  --------- ------------ -------------- ----------------- ---------- -------------- ------------- -------------------- ----------------------- -----------
  CD24      rs52812045   Allele         G                 244        59.5           411           65.9                 1.000                   
                                        A                 166        40.5           213           34.1                 0.754 (0.580--0.981)    **0.035**
  FCRL3     rs11264799   Codominant     CC                119        58.0           205           65.7                 1.000                   
                                        TT                3          1.5            11            3.5                  0.544 (0.678--9.547)    0.166
                                        CT                83         40.5           96            30.8                 0.668 (0.458--0.975)    **0.037**
  TNFAIP3   rs10499194   Codominant     CC                160        78.0           277           88.8                 1.000                   
                                        TT                1          0.5            2             0.6                  1.235 (0.106--14.385)   0.866
                                        CT                44         21.5           33            10.6                 0.431 (0.262--0.711)    **0.001**
                         Dominant       CC                160        78.0           292           93.6                 1.000                   
                                        TT/CT             45         22.0           20            6.4                  0.249 (0.141--0.440)    **0.000**
                         Allele         C                 364        88.8           587           94.1                 1.000                   
                                        T                 46         11.2           37            5.9                  0.499 (0.315--0.791)    **0.003**

*SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio; ITP, immune thrombocytopenia*.

*Adjusted p value calculated with univariate logistic regression*.

*Bold highlights statistical significance (*p* \< 0.05)*.

Next, we performed a multivariate logistic regression analysis under the codominant model. We found that the heterozygous genotypes of *FCRL3* rs11264799 and *TNFAIP3* rs10499194 significantly decreased the risk of ITP compared with homozygous major alleles (*p* = 0.029 and *p* = 0.001, respectively, Table [4](#T4){ref-type="table"}). When we analyzed the combined influence of allelic distribution of both *CD24* rs52812045 and *TNFAIP3* rs10499194, we found a statistical difference in *TNFAIP3* rs10499194 between ITP patients and controls (*p* = 0.006, Table [5](#T5){ref-type="table"}).

###### 

Association between selected SNPs and ITP risk under codominant model.

  Genes     SNP          Genotype   Controls   ITP patients   OR (95% CI)   Adjusted *p* value                           
  --------- ------------ ---------- ---------- -------------- ------------- -------------------- ----------------------- -----------
  FCRL3     rs11264799   CC         119        58.0           205           65.7                 1.000                   
                         TT         3          1.5            11            3.5                  2.703 (0.719--10.161)   0.141
                         CT         83         40.5           96            30.8                 0.653 (0.446--0.958)    **0.029**
  TNFAIP3   rs10499194   CC         160        78.0           277           88.8                 1.000                   
                         TT         1          0.5            2             0.6                  1.285 (0.104--15.869)   0.845
                         CT         44         21.5           33            10.6                 0.415 (0.250--0.689)    **0.001**

*SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio; ITP, immune thrombocytopenia*.

*Adjusted p value calculated with multivariate logistic regression*.

*Bold highlights statistical significance (*p* \< 0.05)*.

###### 

Association between selected SNPs and ITP risk in allelic analysis.

  Genes     SNP          Allele   Controls   ITP patients   OR (95% CI)   Adjusted *p* value                           
  --------- ------------ -------- ---------- -------------- ------------- -------------------- ----------------------- -----------
  CD24      rs52812045   G        244        59.5           411           65.9                 1                       
                         A        166        40.5           213           34.1                 0.785 (0.0620--1.023)   0.073
  TNFAIP3   rs10499194   C        364        88.8           587           94.1                 1.000                   
                         T        46         11.2           37            5.9                  0.522 (0.329--0.829)    **0.006**

*SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio; ITP, immune thrombocytopenia*.

*Adjusted p value calculated with multivariate logistic regression*.

*Bold highlights statistical significance (*p* \< 0.05)*.

Association between Inflammation-Related SNPs and ITP Severity {#S3-3}
--------------------------------------------------------------

We next evaluated the association of the inflammation-related SNPs with ITP disease severity. *CARD8* rs2043211 and *TRAF1* rs10818488 genotypes were statistically different between severe and non-severe ITP patients according to chi-squared analyses (*p* \< 0.05, Table S2 in Supplementary Material). However, neither difference persisted after Bonferroni multiple correction. *CARD8* rs2043211 lost the statistical difference after adjusting for age and gender factors by univariate binary logistic regression under dominant model (AA + AT vs. TT: OR = 0.589, 95% CI = 0.343--1.013, *p* = 0.056). After adjusting for age and gender, ITP patients carrying the AG genotype of *TRAF1* rs10818488 showed a 1.713-fold increased risk of developing severe ITP compared with patients carrying major genotype GG under codominant model (OR = 1.713, 95% CI = 1.008--2.911, *p* = 0.047). In summary, only the AG genotype of *TRAF1* rs10818488 increased the risk of severe ITP among patients.

Association between Inflammation-Related SNPs and Corticosteroid Sensitivity {#S3-4}
----------------------------------------------------------------------------

After studying associations with the pathogenesis of ITP, we explored the association between the inflammation-related polymorphisms and the treatment of ITP. Specifically, we studied corticosteroid sensitivity and refractoriness among patients with different genotypes or alleles. To study corticosteroid sensitivity, we divided the patients who received corticosteroid treatment into two groups, the corticosteroid-sensitive group (*n* = 156) and the corticosteroid-resistant group (*n* = 106).

We found statistically significant associations between inflammation-related polymorphisms and corticosteroid sensitivity. rs945635, rs7528684, and rs3761959 of *FCRL3* and rs2004640 of *IRF5* under the dominant model were significantly associated with corticosteroid-sensitivity (*p* \< 0.05, Table S3 in Supplementary Material). rs4353135 of *NLRP3* under both the codominant and recessive models showed significant association with corticosteroid sensitivity (*p* \< 0.05, Table S3 in Supplementary Material). Allelic frequencies and genotypic frequencies under the codominant and dominant models of *TNFAIP3* rs10499194 revealed statistically significant differences between the corticosteroid-sensitive and corticosteroid-resistant groups (*p* \< 0.05, Table S3 in Supplementary Material). *TNFAIP3* rs10499194 remained significant after Bonferroni multiple correction.

Allelic and genotypic frequencies were analyzed by logistic regression analysis. After univariate logistic regression analysis, compared with major allele homozygotes, minor allele homozygotes, and heterozygotes of *FCRL3* rs945635, rs7528684, and rs3761959 and *IRF* rs2004640 were still significantly associated with corticosteroid-sensitivity under the dominant model after adjusting for age and gender (*p* = 0.029, *p* = 0.029, *p* = 0.029, *p* = 0.024, respectively, Table [6](#T6){ref-type="table"}). Genotypic frequencies of *NLRP3* rs4353135 were significantly different under the recessive model between the corticosteroid-sensitive and -resistant groups (*p* = 0.028, Table [6](#T6){ref-type="table"}). Genotypic and allelic frequencies of *TNFAIP3* rs10499194 were significantly different under the codominant and dominant models (all *p* = 0.001, Table [6](#T6){ref-type="table"}). Importantly, the observed differences in *TNFAIP3* rs10499194 were still statistically significant after Bonferroni multiple correction (*p* \< 0.002).

###### 

Association between selected SNPs and corticosteroid-sensitivity of ITP patients.

  Gene      SNP          Model/allele   Genotype/allele   Sensitive   Resistant   OR (95% CI)[\*](#tfn1){ref-type="table-fn"}   *p* Value[\*](#tfn1){ref-type="table-fn"}   OR (95% CI)^\#^        *p* Value^\#^                          
  --------- ------------ -------------- ----------------- ----------- ----------- --------------------------------------------- ------------------------------------------- ---------------------- --------------- ---------------------- -----------
  TNFAIP3   rs10499194   Codominant     CC                128         82.1        104                                           98.1                                        1                                                             
                                        TT                2           1.3         0                                             0.0                                         --                     0.999                                  
                                        CT                26          16.7        2                                             1.9                                         0.092 (0.021--0.398)   **0.001**                              
                         Dominant       CC                128         82.1        104                                           98.1                                        1.000                                  1.000                  
                                        TT/CT             28          17.9        2                                             1.9                                         0.086 (0.020--0.369)   **0.001**       0.069 (0.016--0.302)   **0.000**
                         Allele         C                 282         90.4        210                                           99.1                                        1.000                                                         
                                        T                 30          9.6         2                                             0.9                                         0.088 (0.021--0.372)   **0.001**                              
  IRF5      rs2004640    Dominant       GG                96          61.5        51                                            48.1                                        1.000                                  1.000                  
                                        TT/GT             60          38.5        55                                            51.9                                        1.793 (1.079--2.980)   **0.024**       1.996 (1.162--3.429)   **0.012**
  FCRL3     rs3761959    Dominant       CC                65          41.7        30                                            28.3                                        1.000                                  1.000                  
                                        TT/CT             91          58.3        76                                            71.7                                        1.807 (1.062--3.076)   **0.029**       2.107 (1.208--3.674)   **0.009**
  FCRL3     rs7528684    Dominant       AA                65          41.7        30                                            28.3                                        1.000                                  1.000                  
                                        GG/AG             91          58.3        76                                            71.7                                        1.807 (1.062--3.076)   **0.029**       2.107 (1.208--3.674)   **0.009**
  FCRL3     rs945635     Dominant       CC                65          41.7        30                                            28.3                                        1.000                                  1.000                  
                                        GG/CG             91          58.3        76                                            71.7                                        1.807 (1.062--3.076)   **0.029**       2.107 (1.208--3.674)   **0.009**
  NLRP3     rs4353135    Codominant     TT                49          31.4        36                                            34.0                                        1.000                                                         
                                        GG                24          15.4        29                                            27.4                                        1.599 (0.798--3.205)   0.186                                  
                                        GT                83          53.2        41                                            38.7                                        0.684 (0.385--1.212)   0.193                                  
                         Recessive      TT/GT             132         84.6        77                                            72.6                                        1.000                                                         
                                        GG                24          15.4        29                                            27.4                                        1.991 (1.077--3.681)   **0.028**                              

*SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio; ITP, immune thrombocytopenia*.

*\*Calculated by univariate logistic regression*.

*^\#^Calculated by multivariate logistic regression analysis under dominant model*.

*Bold highlights statistical significance (*p* \< 0.05)*.

Multivariate logistic regression showed significant associations between *FCRL3* rs945635, rs7528684, and rs3761959, *IRF* rs2004640, and *TNFAIP3* rs10499194 and corticosteroid sensitivity (*p* = 0.009, *p* = 0.009, *p* = 0.009, *p* = 0.012, and *p* = 0.000, respectively, Table [6](#T6){ref-type="table"}). *TNFAIP3* rs10499194 was significantly associated with corticosteroid-sensitivity under both univariate and multivariate logistic regression analyses after Bonferroni multiple correction (*p* \< 0.002).

Association between Inflammation-Related SNPs and ITP Refractoriness {#S3-5}
--------------------------------------------------------------------

To study refractoriness, we divided the enrolled patients into two subgroups: those refractory to splenectomy treatment and those who responded to medical treatment. We analyzed the association between the inflammation-related SNPs and refractoriness of ITP using chi-squared tests for preliminary screening. The genotypic distribution of *STAT4* rs7574869 was significantly associated with refractoriness under the codominant model (*p* \< 0.05, Table S4 in Supplementary Material). No statistical differences were found between other SNPs and refractoriness (*p* \> 0.05). However, the association between *STAT4* rs7574869 and refractoriness was not statistically significant after Bonferroni multiple correction. When the GG genotype was used as reference, neither the TT nor GT genotypes were significantly associated with refractoriness after adjusting for the age and gender (*p* = 0.998 and *p* = 0.108, respectively).

Association of TNFAIP3 rs10499194 Polymorphism and Expression Levels of TNFAIP3 {#S3-6}
-------------------------------------------------------------------------------

To determine whether *TNFAIP3* rs10499194 was a protective factor for ITP, we further explored the effects of this polymorphism on *TNFAIP3* expression. The number of ITP patients with TT genotype was small (*n* = 2) in this study, which may lead to an underpowered assessment. The expression of *TNFAIP3* was assessed in 85 ITP patients (60 cases of CC, 2 cases of TT, and 23 cases of CT) by quantitative real-time RT-PCR. As shown in Figure [1](#F1){ref-type="fig"}A, patients with CT genotype showed higher levels of TNFAIP3 mRNA expression than those with CC genotype (*p* = 0.001). We found that TNFAIP3 expression was significantly higher in samples with pooled CT/TT genotype compared with the CC genotype (*p* = 0.001; Figure [1](#F1){ref-type="fig"}B). The result showed that CC genotype on *TNFAIP3* rs10499194 was a protective factor for ITP.

![**(A)** Expression of TNFAIP3 mRNA in ITP patients with the CC, CT and TT genotypes. **(B)** Expression of TNFAIP3 mRNA in ITP patients with the CC and pooled CT/TT genotypes.](fimmu-08-00744-g001){#F1}

Discussion {#S4}
==========

Immune thrombocytopenia is an autoimmune and inflammatory disease characterized by immune-mediated platelet destruction. Although ITP has been associated with inflammation, only a few studies have identified the association between inflammation-related SNPs and the pathogenesis of ITP ([@B43]). By contrast, inflammation-related gene polymorphisms have been associated with multiple autoimmune diseases.

In this study, we assessed the associations between 25 inflammation-related SNPs and the occurrence and treatment of ITP in the Chinese Han population. Of these SNPs, the frequencies of the homozygous minor allele of *FCRL3* rs11264799 and *TNFAIP3* rs10499194 were significantly decreased in ITP patients. The A allele of *CD24* rs8734 was associated with a decreased risk of ITP. In addition, compared with the CC genotype, individuals carrying pooled TT/CT genotypes of *TNFAIP3* rs10499194 had a decreased risk of ITP under the dominant model. These three SNPs were all protective factors.

Our findings contrast evidence found regarding other autoimmune diseases ([@B26], [@B44]--[@B48]). For example, in the Spanish population, no association was found between *FCRL3* rs11264799 and MS ([@B44]). Interestingly, however, the C allele of *FCRL3* rs7528684 was a protective factor for MS. This suggests that *FCRL3* polymorphisms may protect individuals from autoimmune diseases, which is somewhat consistent with our findings. In the Israeli population, individuals with *CD24* rs8734 polymorphisms had an increased risk of IBD, ulcerative colitis, and Crohn's disease ([@B26]). In the Chinese population, a significant association was not found between *TNFAIP3* rs10499194 and SLE ([@B45]); however, carriers of the CT genotype and combined TT/CT genotype had an increased risk for RA in the Chinese Han population ([@B46]). A recent meta-analysis revealed that there was no association between *TNFAIP3* rs10499194 and RA in Europeans, but a significant association in Asians (OR = 1.254, 95% CI = 1.101--1.429, *p* = 6.7 × 10^−4^) ([@B48]). The discrepancies between our results and previous research may be attributed to differences in the populations and autoimmune diseases studied.

When it comes to *TNFAIP3* rs10499194, there were several researches identified that it was significantly associated with the susceptibility of autoimmune diseases. Strong associations were observed between *TNFAIP3* rs10499194 and juvenile idiopathic arthritis (OR = 0.74, 95% CI = 0.61--0.91, *p* \< 0.004) ([@B49]). Prahalad et al demonstrated that *TNFAIP3* rs10499194 had a significant protective effect against childhood onset RA (OR = 0.60, 95% CI = 0.44--0.83, *p* = 0.002) ([@B50]). Consistent with our findings, *TNFAIP3* rs2230926 and rs5029939 were significantly different between chronic ITP and control groups ([@B43]), suggesting that *TNFAIP3* polymorphisms may affect the susceptibility to ITP. We found that *TNFAIP3* rs10499194 was significantly associated with the susceptibility of ITP even after Bonferroni multiple correction. Therefore, *TNFAIP3* rs10499194 may be an important susceptibility-related SNP for ITP.

To investigate whether *TNFAIP3* rs10499194 was a functional polymorphism, quantitative real-time RT-PCR was performed to evaluate *TNFAIP3* expression. The data showed that individuals with CT genotype on *TNFAIP3* rs10499194 locus showed higher levels of TNFAIP3 mRNA expression compared with the CC genotype, which might play a role in the susceptibility of ITP. It is widely accepted that *TNFAIP3* is a deubiquitinating protein which can deregulate pro-inflammatory signal pathways including NF-κB- and IRF3-dependent gene expression by deubiquitinating specific signaling molecules ([@B51], [@B52]). Some researchers revealed that TNFAIP3 was a central gatekeeper in inflammation and immunity ([@B53]). A recent study demonstrated that lack of TNFAIP3 in B cells resulted in overexpression of pro-inflammatory cytokines, which caused inflammation and autoimmunity in aged mice ([@B54]). TNFAIP3-deficient B cells displayed enhanced proliferation and development of autoantibodies ([@B55]). In our functional analysis, individuals with CT genotype on *TNFAIP3* rs10499194 locus showed higher levels of TNFAIP3 mRNA expression compared with the wild genotype CC, which is in agreement with our genotyping analysis that CT genotype is a protective factor for ITP. However, the mechanism of polymorphism on TNFAIP3 expression awaits further investigations.

Furthermore, we found that the AG genotype of *TRAF1* rs10818488 was significantly associated with increased risk of severe ITP after adjusting for age and gender. These novel findings will be studied further in order to understand the molecular mechanism of these genetic polymorphisms.

In addition to the pathogenesis of ITP, the mechanism of corticosteroid resistance remains poorly understood. In acute lymphoblastic leukemia, the NLRP3-CASP1 inflammasome induced glucocorticoid resistance ([@B56]). Overexpression of CASP1 may promote cleavage of the glucocorticoid receptor, which decreased glucocorticoid sensitivity. We identified that *NLRP3* rs4353135 was significantly associated with increased risk of corticosteroid resistance of ITP under the recessive model; however, this observation was not significant after Bonferroni multiple correction. Thus, we propose that the *NLRP3* rs4353135 polymorphism may enhance expression of the NLRP3-CASP1 inflammasome and lead to corticosteroid resistance. Future studies will examine this hypothesis.

Importantly, *TNFAIP3* rs10499194 was associated with corticosteroid-sensitivity after Bonferroni correction. Future work will examine the potential of *TNFAIP3* rs10499194 as a biomarker for corticosteroid sensitivity.

There were some limitations to our study. On the one hand, the participants enrolled in our study were solely from Chinese Han population. Larger trials investigating multi-racial populations are needed to examine whether the associations between the inflammation-related SNPs and ITP exist in the general population. Second, as mentioned earlier, the biological functions and signaling pathways of these SNPs are not yet known and future research with global collaborations are required. Third, there was a potential selection bias in our study. Only inpatients were recruited in our study, as the corticosteroid-sensitivity and refractoriness of outpatients were difficult to follow-up in our hospital. The inpatients have more severe thrombocytopenia and bleeding symptoms. The bleeding symptoms may include gastrointestinal hemorrhage, extensive skin and mucosal hemorrhage, or intracranial hemorrhage. Besides, the 25 susceptibility loci, we tested were selected basing on the pervious reported loci associated with other autoimmune diseases. The candidate gene approach cannot cover all susceptible loci, which may lead to the selection bias.

Conclusion {#S5}
==========

Our investigation of SNPs and ITP provides interesting results. We found that inflammation-related SNPs, especially *TNFAIP3* rs10499194, may be genetic risk factors associated with the development and treatment of ITP. Our findings may lead to clinicians screening for these SNPs in order to predict the prognosis and guide the treatment of ITP.
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